The therapeutic target Hsp90 and cancer hallmarks

Current Pharmaceutical Design

Volumn 19, Issue 3, 2013, Pages 347-365

  Miyata, Yoshihiko ^a   Nakamoto, Hitoshi ^b   Neckers, Len ^c  

^a KYOTO UNIVERSITY   (Japan)

^b SAITAMA UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cdc37; CK2; Co chaperone; Geldanamycin; Hsp90; Protein kinase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AHA1 PROTEIN; CASEIN KINASE II; CELL CYCLE PROTEIN 37; CHAPERONE; CRIZOTINIB; CYCLIN DEPENDENT KINASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HOP PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P23; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; STEROID RECEPTOR; TELOMERASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACETYLATION; ADD ON THERAPY; ANGIOGENESIS; APOPTOSIS; ATTENUATION; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; LUNG NON SMALL CELL CANCER; MITOSIS; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TREATMENT RESPONSE;

EID: 84874267225     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804143725     Document Type: Review

References (271)

1. Csermely P, Schnaider T, Söti C, Prohászka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998; 79: 129-68.
2. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275: 3305-12.
3. Schmitz G, Schmidt M, Feierabend J. Characterization of a plastidspecific HSP90 homologue: identification of a cDNA sequence, phylogenetic descendence and analysis of its mRNA and protein expression. Plant Mol Biol 1996; 30: 479-92.
4. Shiu RP, Pouyssegur J, Pastan I. Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci USA 1977; 74: 3840-4.
5. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E. A mouse tumor-specific transplantation antigen is a heat shockrelated protein. Proc Natl Acad Sci USA 1986; 83: 3121-5.
6. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007; 98: 1536-9
7. Bardwell JC, Craig EA. Eukaryotic Mr 83,000 heat shock protein has a homologue in Escherichia coli. Proc Natl Acad Sci USA 1987; 84: 5177-81.
8. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006; 75: 271-94.
9. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-7.
10. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADPbinding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
11. Krukenberg KA, Street TO, Lavery LA, Agard DA. Conformational dynamics of the molecular chaperone Hsp90. Q Rev Biophys 2011; 44: 229-55.
12. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89: 239-50.
13. Roe SM, Ali MM, Meyer P, et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004; 116: 87-98.
14. Ali MM, Roe SM, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006; 440: 1013-7.
15. Prodromou C, Panaretou B, Chohan S, et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 2000; 19: 4383-92.
16. Meyer P, Prodromou C, Hu B, et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 2003; 11: 647-58.
17. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-7.
18. Fontana J, Fulton D, Chen Y, et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002; 90: 866-73.
19. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006; 23: 697-707.
20. Sato T, Minagawa S, Kojima E, Okamoto N, Nakamoto H. HtpG, the prokaryotic homologue of Hsp90, stabilizes a phycobilisome protein in the cyanobacterium Synechococcus elongatus PCC 7942. Mol Microbiol 2010; 76: 576-89.
21. Street TO, Lavery LA, Agard DA. Substrate binding drives largescale conformational changes in the Hsp90 molecular chaperone. Mol Cell 2011; 42: 96-105.
22. Meyer P, Prodromou C, Liao C, et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 2004; 23: 1402-10.
23. Minami Y, Kimura Y, Kawasaki H, Suzuki K, Yahara I. The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol Cell Biol 1994;14: 1459-64.
24. Nemoto T, Ohara-Nemoto Y, Ota M, Takagi T, Yokoyama K. Mechanism of dimer formation of the 90-kDa heat-shock protein. Eur J Biochem 1995; 233: 1-8.
25. Harris SF, Shiau AK, Agard DA. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. Structure 2004; 12: 1087-97.
26. Hagn F, Lagleder S, Retzlaff M, et al. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol 2011; 18: 1086-93.
27. Shiau AK, Harris SF, Southworth DR, Agard DA. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006; 127: 329-40.
28. Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 2007; 28: 41-56.
29. Southworth DR, Agard DA. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. Mol Cell 2008; 32: 631-40.
30. Krukenberg KA, Southworth DR, Street TO, Agard DA. pHdependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation. J Mol Biol 2009; 390: 278-91.
31. Mickler M, Hessling M, Ratzke C, Buchner J, Hugel T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nat Struct Mol Biol 2009; 16: 281-6.
32. Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998; 17: 4829-36.
33. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 1998; 143: 901-10.
34. Prodromou C. The 'active life' of Hsp90 complexes. Biochim Biophys Acta 2012; 1823: 614-23.
35. McLaughlin SH, Ventouras LA, Lobbezoo B, Jackson SE. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J Mol Biol 2004; 344: 813-26.
36. Hessling M, Richter K, Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat Struct Mol Biol 2009; 16: 287-93.
37. Young JC, Hartl FU. Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMBO J 2000; 19: 5930-40.
38. Walerych D, Gutkowska M, Klejman MP, et al. ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein. J Biol Chem 2010; 285: 32020-8.
39. McLaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol 2002; 315: 787-98.
40. Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005; 120: 715-27.
41. Brugge JS. Interaction of the Rous sarcoma virus protein pp60src with the cellular proteins pp50 and pp90. Curr Top Microbiol Immunol 1986; 123: 1-22.
42. Whitesell L, Geselowitz D, Chavany C, et al. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 1993; 90: 4665-9.
43. Xu Y, Lindquist S. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc Natl Acad Sci USA 1993; 90: 7074-8.
44. Xu Y, Singer MA, Lindquist S. Maturation of the tyrosine kinase csrc as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci USA 1999; 96: 109-14.
45. Falsone SF, Leptihn S, Osterauer A, Haslbeck M, Buchner J. Oncogenic mutations reduce the stability of Src kinase. J Mol Biol 2004; 344: 281-91.
46. Rüdiger S, Freund SM, Veprintsev DB, Fersht AR. CRINEPTTROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci USA 2002; 99: 11085-90.
47. Zuehlke A, Johnson JL. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2010; 93: 211-7.
48. Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta 2012; 1823: 624-35.
49. Das AK, Cohen PW, Barford D. The structure of the tetratricopeptide repeats of protein phosphatase 5: implications for TPRmediated protein-protein interactions. EMBO J 1998; 17: 1192-9.
50. Scheufler C, Brinker A, Bourenkov G, et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000; 101: 199-210.
51. Catlett MG, Kaplan KB. Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p. J Biol Chem 2006; 281: 33739-48.
52. Koulov AV, Lapointe P, Lu B, et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell 2010; 21: 871-84.
53. McDowell CL, Bryan Sutton R, Obermann WM. Expression of Hsp90 chaperone proteins in human tumor tissue. Int J Biol Macromol 2009; 45: 310-4.
54. Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008; 68: 1188-97.
55. Prodromou C, Siligardi G, O'Brien R, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain cochaperones. EMBO J 1999; 18: 754-62.
56. Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J Biol Chem 2003; 278: 10328-33.
57. Pratt WB, Morishima Y, Murphy M, Harrell M. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 2006; 172: 111-38.
58. Southworth DR, Agard DA. Client-loading conformation of the Hsp90 molecular chaperone revealed in the cryo-EM structure of the human Hsp90:Hop complex. Mol Cell 2011; 42: 771-81.
59. Li J, Richter K, Buchner J. Mixed Hsp90-cochaperone complexes are important for the progression of the reaction cycle. Nat Struct Mol Biol 2011; 18: 61-6.
60. Chen S, Smith DF. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem 1998; 273: 35194-200.
61. Brinker A, Scheufler C, Von der Mülbe F, et al. Ligand discrimination by TPR domains. Relevance and selectivity of EEVDrecognition in Hsp70 Hop Hsp90 complexes. J Biol Chem 2002; 277: 19265-75.
62. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002; 10: 1307-18.
63. Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J Biol Chem 2004; 279: 51989-98.
64. McLaughlin SH, Sobott F, Yao ZP, et al. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J Mol Biol 2006; 356: 746-58.
65. Siligardi G, Panaretou B, Meyer P, et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem 2002; 277: 20151-9.
66. Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH. p50cdc37 acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 1999; 19: 1661-72.
67. Pearl LH. Hsp90 and Cdc37--a chaperone cancer conspiracy. Curr Opin Genet Dev 2005; 15: 55-61.
68. cdc37 function during the biogenesis of the activeconformation of the heme-regulated eIF2α kinase. J Biol Chem 2001; 276: 206-14.
69. Silverstein AM, Grammatikakis N, Cochran BH, Chinkers M, Pratt WB. p50cdc37 binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J Biol Chem 1998; 273: 20090-5.
70. Millson SH, Vaughan CK, Zhai C, et al. Chaperone liganddiscrimination by the TPR-domain protein Tah1. Biochem J 2008; 413: 261-8.
71. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 2003; 278: 17228-35.
72. Retzlaff M, Hagn F, Mitschke L, et al. Asymmetric activation of the hsp90 dimer by its cochaperone Aha1. Mol Cell 2010; 37: 344-54.
73. Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 2012; 1823: 648-55.
74. Adinolfi E, Kim M, Young MT, Di Virgilio F, Surprenant A. Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex negatively regulates P2X7 receptors. J Biol Chem 2003; 278: 37344-51.
75. Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2011; 2: 407-17.
76. Mollapour M, Tsutsumi S, Truman AW, et al. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell 2011; 41: 672-81.
77. Mollapour M, Tsutsumi S, Donnelly AC, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 2010; 37: 333-43.
78. Xu W, Mollapour M, Prodromou C, et al. Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50CDC37-AHA1 chaperone machine. Mol Cell 2012; 47: 434-43.
79. Mimnaugh EG, Worland PJ, Whitesell L, Neckers LM. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J Biol Chem 1995; 270: 28654-9.
80. Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J 2006; 25: 367-76.
81. Duval M, Le Boeuf F, Huot J, Gratton JP. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell 2007; 18: 4659-68.
82. Lei H, Venkatakrishnan A, Yu S, Kazlauskas A. Protein kinase Adependent translocation of Hsp90α impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem 2007; 282: 9364-71.
83. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369: 1-15.
84. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003; 17: 349-68.
85. Miyata Y. CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 2009; 66: 1840-9.
86. Lees-Miller SP, Anderson CW. Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J Biol Chem 1989; 264: 2431-7.
87. Kurokawa M, Zhao C, Reya T, Kornbluth S. Inhibition of apoptosome formation by suppression of Hsp90α phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol 2008; 28: 5494-506.
88. Ogiso H, Kagi N, Matsumoto E, et al. Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry 2004; 43: 15510-9.
89. Cunningham CN, Krukenberg KA, Agard DA. Intra-and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J Biol Chem 2008; 283: 21170-8.
90. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94: 504-13.
91. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-34.
92. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-7.
93. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009; 284: 7436-45.
94. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion. Cancer Res 2008; 68: 4833-42.
95. Park JH, Kim SH, Choi MC, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368: 318-22.
96. Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008; 28: 1688-701.
97. Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 2009; 23: 1963-72.
98. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 2008; 6: 873-83.
99. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007; 25: 151-9.
100. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
101. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-7.
102. Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 2005; 1: 273-81.
103. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206: 149-57.
104. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
105. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol 2006; 259-77.
106. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006; 31: 164-72.
107. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
108. Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2010; 2: 238-47.
109. Castelli C, Rivoltini L, Rini F, et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2004; 53: 227-33.
110. Li Z, Dai J, Zheng H, Liu B, Caudill M. An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. Front Biosci 2002; 7: d731-51.
111. Stock J. Signal transduction: Gyrating protein kinases. Curr Biol 1999; 9: R364-R7.
112. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001; 188: 281-90.
113. Sreedhar AS, Söti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004; 1697: 233-42.
114. Caplan AJ, Mandal AK, Theodoraki MA. Molecular chaperones and protein kinase quality control. Trends Cell Biol 2007; 17: 87-92.
115. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
116. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer 2012; 12: 19-29.
117. Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996; 271: 4974-7.
118. Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001; 276: 3702-8.
119. Takata Y, Imamura T, Iwata M, et al. Functional importance of heat shock protein 90 associated with insulin receptor on insulinstimulated mitogenesis. Biochem Biophys Res Commun 1997; 237: 345-7.
120. Imamura T, Haruta T, Takata Y, et al. Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome. J Biol Chem 1998; 273: 11183-8.
121. Ramos RR, Swanson AJ, Bass J. Calreticulin and Hsp90 stabilize the human insulin receptor and promote its mobility in the endoplasmic reticulum. Proc Natl Acad Sci USA 2007; 104: 10470-5.
122. Martins AS, Ordoñez JL, García-Sánchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to antiinsulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008; 68: 6260-70.
123. Wrighton KH, Lin X, Feng XH. Critical regulation of TGF[signaling by Hsp90. Proc Natl Acad Sci USA 2008; 105: 9244-9.
124. Schwartzberg PL. The many faces of Src: multiple functions of a prototypical tyrosine kinase. Oncogene 1998; 17: 1463-8.
125. Brugge JS, Erikson E, Erikson RL. The specific interaction of the Rous sarcoma virus transforming protein, pp60src, with two cellular proteins. Cell 1981; 25: 363-72.
126. Perdew GH, Wiegand H, Vanden Heuvel JP, Mitchell C, Singh SS. A 50 kilodalton protein associated with raf and pp60v-src protein kinases is a mammalian homolog of the cell cycle control protein cdc37. Biochemistry 1997; 36: 3600-7.
127. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8.
128. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcrabl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11: 355-60.
129. Giannini A, Bijlmakers MJ. Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol Cell Biol 2004; 24: 5667-76.
130. Ziemiecki A, Catelli MG, Joab I, Moncharmont B. Association of the heat shock protein hsp90 with steroid hormone receptors and tyrosine kinase oncogene products. Biochem Biophys Res Commun 1986; 138: 1298-307.
131. Lipsich LA, Cutt JR, Brugge JS. Association of the transforming proteins of Rous, Fujinami, and Y73 avian sarcoma viruses with the same two cellular proteins. Mol Cell Biol 1982; 2: 875-80.
132. Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia--how does it work? Acta Haematol 2008; 119: 212-7.
133. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90.
134. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010; 661: 3-38.
135. Roskoski R, Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010; 399: 313-7.
136. Leicht DT, Balan V, Kaplun A, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007; 1773: 1196-212.
137. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9: 174-9.
138. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-83.
139. Stancato LF, Chow YH, Owens-Grillo JK, et al. The native v-Raf·hsp90·p50 heterocomplex contains a novel immunophilin of the FK506 binding class. J Biol Chem 1994; 269: 22157-61.
140. Miyata Y, Nishida E. Distantly related cousins of MAP kinase: Biochemical properties and possible physiological functions. Biochem Biophys Res Commun 1999; 266: 291-5.
141. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996; 44: 323-30.
142. Götte K, Usener D, Riedel F, Hörmann K, Schadendorf D, Eichmüller S. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: Comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol 2002; 122: 546-52.
143. Miyata Y, Ikawa Y, Shibuya M, Nishida E. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the MAP kinase superfamily. J Biol Chem 2001; 276: 21841-8.
144. Chen N, Mah A, Blacque OE, et al. Identification of ciliary and ciliopathy genes in Caenorhabditis elegans through comparative genomics. Genome Biol 2006; 7: R126.
145. Burghoorn J, Dekkers MP, Rademakers S, de Jong T, Willemsen R, Jansen G. Mutation of the MAP kinase DYF-5 affects docking and undocking of kinesin-2 motors and reduces their speed in the cilia of Caenorhabditis elegans. Proc Natl Acad Sci USA 2007; 104: 7157-62.
146. Berman SA, Wilson NF, Haas NA, Lefebvre PA. A novel MAP kinase regulates flagellar length in Chlamydomonas. Curr Biol 2003; 13: 1145-9.
147. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30: 630-41.
148. Nurse P. Cyclin dependent kinases and cell cycle control (Nobel Lecture). Chembiochem 2002; 3: 596-603.
149. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-72.
150. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491-502.
151. Lamphere L, Fiore F, Xu X, et al. Interaction between Cdc37 and Cdk4 in human cells. Oncogene 1997; 14: 1999-2004.
152. Dai K, Kobayashi R, Beach D. Physical interaction of mammalian CDC37 with CDK4. J Biol Chem 1996; 271: 22030-4.
153. Berry LD, Gould KL. Regulation of Cdc2 activity by phosphorylation at T14/Y15. Prog Cell Cycle Res 1996; 2: 99-105.
154. Domingo-Sananes MR, Kapuy O, Hunt T, Novak B. Switches and latches: a biochemical tug-of-war between the kinases and phosphatases that control mitosis. Philos Trans R Soc Lond B Biol Sci 2011; 366: 3584-94.
155. Aligue R, Akhavan-Niak H, Russell P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J 1994; 13: 6099-106.
156. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10: 825-41.
157. Nigg EA. Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998; 10: 776-83.
158. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10: 265-75.
159. Shimizu S, Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000; 2: 852-4.
160. De Cárcer G, Do Carmo Avides M, Lallena MJ, Glover DM, González C. Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J 2001; 20: 2878-84.
161. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54.
162. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786: 60-72.
163. Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009; 52: 2629-51.
164. Lange BM, Rebollo E, Herold A, González C. Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes. EMBO J 2002; 21: 5364-74.
165. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATRChk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108: 73-112.
166. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006; 281: 2989-98.
167. Felts SJ, Karnitz LM, Toft DO. Functioning of the Hsp90 machine in chaperoning checkpoint kinase I (Chk1) and the progesterone receptor (PR). Cell Stress Chaperones 2007; 12: 353-63.
168. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499-504.
169. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs 2005; 16: 1037-43.
170. Pinna LA, Meggio F. Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. Prog Cell Cycle Res 1997; 3: 77-97.
171. Filhol O, Martiel JL, Cochet C. Protein kinase CK2: a new view of an old molecular complex. EMBO reports 2004; 5: 351-5.
172. Olsten ME, Litchfield DW. Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem Cell Biol 2004; 82: 681-93.
173. Pinna LA. The raison d'être of constitutively active protein kinases: the lesson of CK2. Acc Chem Res 2003; 36: 378-84.
174. Xu X, Landesman-Bollag E, Channavajhala PL, Seldin DC. Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem 1999; 191: 65-74.
175. Seldin DC, Leder P. Casein kinase II [transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995; 267: 894-7.
176. Miyata Y, Yahara I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J Biol Chem 1992; 267: 7042-7.
177. Miyata Y, Yahara I. Interaction between casein kinase II and the 90-kDa stress protein, HSP90. Biochemistry 1995; 34: 8123-9.
178. Hunter T, Poon RYC. Cdc37: a protein kinase chaperone? Trends Cell Biol 1997; 7: 157-61.
179. MacLean M, Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 2003; 8: 114-9.
180. Gray PJ, Jr., Prince T, Cheng J, Stevenson MA, Calderwood SK. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 2008; 8: 491-5.
181. Miyata Y, Nishida E. Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target. Ann NY Acad Sci 2004; 1030: 150-7.
182. Bandhakavi S, McCann RO, Hanna DE, Glover CVC. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J Biol Chem 2003; 278: 2829-36.
183. Dey B, Lightbody JJ, Boschelli F. CDC37 is required for p60v-src activity in yeast. Mol Biol Cell 1996; 7: 1405-17.
184. Fliss AE, Fang Y, Boschelli F, Caplan AJ. Differential in vivo regulation of steroid hormone receptor activation by Cdc37p. Mol Biol Cell 1997; 8: 2501-9.
185. Abbas-Terki T, Donze O, Picard D. The molecular chaperone Cdc37 is required for Ste11 function and pheromone-induced cell cycle arrest. FEBS Lett 2000; 467: 111-6.
186. Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone Cdc37. Mol Cell Biol 2004; 24: 4065-74.
187. Shao J, Prince T, Hartson SD, Matts RL. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J Biol Chem 2003; 278: 38117-220.
188. Kimura Y, Rutherford SL, Miyata Y, et al. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 1997; 11: 1775-85.
189. Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009; 28: 157-69.
190. Smith JR, Workman P. Targeting CDC37: an alternative, kinasedirected strategy for disruption of oncogenic chaperoning. Cell Cycle 2009; 8: 362-72.
191. Miyata Y, Nishida E. Analysis of the CK2-dependent phosphorylation of serine 13 in Cdc37 using a phospho-specific antibody and phospho-affinity gel electrophoresis. FEBS J 2007; 274: 5690-703.
192. Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010; 123: 2527-732.
193. Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2010; 2: a000893.
194. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998; 18: 1517-24.
195. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 1996; 93: 8379-83.
196. Sepehrnia B, Paz IB, Dasgupta G, Momand J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 1996; 271: 15084-90.
197. Wang C, Chen J. Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem 2003; 278: 2066-71.
198. Nagata Y, Anan T, Yoshida T, et al. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wildtype p53 function and the hsp90 association. Oncogene 1999; 18: 6037-49.
199. Walerych D, Kudla K, Gutkowska M, et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 2004; 279: 48836-45.
200. Müller L, Schaupp A, Walerych D, Wegele H, Buchner J. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem 2004; 279: 48846-54.
201. Renault TT, Manon S. Bax: Addressed to kill. Biochimie 2011; 93: 1379-91.
202. Cohen-Saidon C, Carmi I, Keren A, Razin E. Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90e. Blood 2006; 107: 1413-20.
203. Kuo CC, Liang CM, Lai CY, Liang SM. Involvement of heat shock protein (Hsp)90ppbut not Hsp90bbin antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol 2007; 178: 6100-8.
204. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PUH71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009; 106: 8368-73.
205. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-44.
206. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36 Suppl 3: S3-S17.
207. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschläger M. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659: 284-92.
208. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2002; 277: 10346-53.
209. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with Hsp90 and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277: 39858-66.
210. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperone-dependent GSK3VVtransitional intermediate mediates activation-loop autophosphorylation. Mol Cell 2006; 24: 627-33.
211. Banz VM, Medová M, Keogh A, et al. Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3t. Biochim Biophys Acta 2009; 1793: 1597-603.
212. Takai H, Xie Y, de Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev 2010; 24: 2019-30.
213. Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011; 7: 818-26.
214. Lin Y, Hupp TR, Stevens C. Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J 2010; 277: 48-57.
215. Bovellan M, Fritzsche M, Stevens C, Charras G. Death-associated protein kinase (DAPK) and signal transduction: blebbing in programmed cell death. FEBS J 2010; 277: 58-65.
216. Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 2006; 75: 189-210.
217. Zhang L, Nephew KP, Gallagher PJ. Regulation of deathassociated protein kinase. Stabilization by HSP90 heterocomplexes. J Biol Chem 2007; 282: 11795-804.
218. Citri A, Harari D, Shochat G, et al. Hsp90 recognizes a common surface on client kinases. J Biol Chem 2006; 281: 14361-9.
219. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012; 12: 23-38.
220. Vaahtomeri K, Mäkelä TP. Molecular mechanisms of tumor suppression by LKB1. FEBS Lett 2011; 585: 944-51.
221. Nony P, Gaude H, Rossel M, Fournier L, Rouault JP, Billaud M. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. Oncogene 2003; 22: 9165-75.
222. Boudeau J, Deak M, Lawlor MA, Morrice NA, Alessi DR. Heatshock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem J 2003; 370: 849-57.
223. Picard D. Chaperoning steroid hormone action. Trends Endocrinol Metab 2006; 17: 229-35.
224. Kimmins S, MacRae TH. Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins. Cell Stress Chaperones 2000; 5: 76-86.
225. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18: 306-60.
226. Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta 2010; 1803: 641-9.
227. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001; 11: 339-52.
228. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905-31.
229. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 2011; 68: 3971-81.
230. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007; 21: 2855-63.
231. Rao J, Lee P, Benzeno S, et al. Functional interaction of human Cdc37 with the androgen receptor but not with the glucocorticoid receptor. J Biol Chem 2001; 276: 5814-20.
232. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008; 73: 914-21.
233. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998; 58: 627-32.
234. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-9.
235. Gomes NM, Shay JW, Wright WE. Telomere biology in Metazoa. FEBS Lett 2010; 584: 3741-51.
236. Shore D, Bianchi A. Telomere length regulation: coupling DNA end processing to feedback regulation of telomerase. EMBO J 2009; 28: 2309-22.
237. Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer. Nucleic Acids Res 2006; 34: 2408-17.
238. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353-65.
239. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-79.
240. Holt SE, Aisner DL, Baur J, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999; 13: 817-26.
241. DeZwaan DC, Toogun OA, Echtenkamp FJ, Freeman BC. The Hsp82 molecular chaperone promotes a switch between unextendable and extendable telomere states. Nat Struct Mol Biol 2009; 16: 711-6.
242. Grandin N, Charbonneau M. Hsp90 levels affect telomere length in yeast. Mol Genet Genomics 2001; 265: 126-34.
243. Toogun OA, Dezwaan DC, Freeman BC. The hsp90 molecular chaperone modulates multiple telomerase activities. Mol Cell Biol 2008; 28: 457-67.
244. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
245. Mazitschek R, Giannis A. Inhibitors of angiogenesis and cancerrelated receptor tyrosine kinases. Curr Opin Chem Biol 2004; 8: 432-41.
246. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 Suppl 3: 4-10.
247. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-29.
248. Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. J Biol Chem 2011; 286: 19597-604.
249. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006; 5: 522-32.
250. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
251. Soroka J, Wandinger SK, Mäusbacher N, et al. Conformational Switching of the Molecular Chaperone Hsp90 via Regulated Phosphorylation. Mol Cell 2012; 45: 517-28.
252. Miyata Y, Chambraud B, Radanyi C, et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II (CK2): Regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci USA 1997; 94: 14500-5.
253. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 2005; 15: 565-7.
254. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17: 5132-9.
255. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 7535-40.
256. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-43.
257. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-9.
258. Lindquist S. Protein folding sculpting evolutionary change. Cold Spring Harb Symp Quant Biol 2009; 74: 103-8.
259. Sangster TA, Lindquist S, Queitsch C. Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 2004; 26: 348-62.
260. Rutherford S, Hirate Y, Swalla BJ. The Hsp90 capacitor, developmental remodeling, and evolution: the robustness of gene networks and the curious evolvability of metamorphosis. Crit Rev Biochem Mol Biol 2007; 42: 355-72.
261. Yahara I. The role of HSP90 in evolution. Genes Cells 1999; 4: 375-9.
262. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011; 11: 644-56.
263. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010; 101: 2309-15.
264. Miyoshi T, Takeuchi A, Siomi H, Siomi MC. A direct role for Hsp90 in pre-RISC formation in Drosophila. Nat Struct Mol Biol 2010; 17: 1024-6.
265. Gangaraju VK, Yin H, Weiner MM, Wang J, Huang XA, Lin H. Drosophila Piwi functions in Hsp90-mediated suppression of phenotypic variation. Nat Genet 2011; 43: 153-8.
266. Iki T, Yoshikawa M, Nishikiori M, et al. In vitro assembly of plant RNA-induced silencing complexes facilitated by molecular chaperone HSP90. Mol Cell 2010; 39: 282-91.
267. Iwasaki S, Kobayashi M, Yoda M, et al. Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes. Mol Cell 2010; 39: 292-9.
268. Johnston M, Geoffroy MC, Sobala A, Hay R, Hutvagner G. HSP90 protein stabilizes unloaded argonaute complexes and microscopic P-bodies in human cells. Mol Biol Cell 2010; 21: 1462-9.
269. Pare JM, Tahbaz N, Lopez-Orozco J, LaPointe P, Lasko P, Hobman TC. Hsp90 regulates the function of argonaute 2 and its recruitment to stress granules and P-bodies. Mol Biol Cell 2009; 20: 3273-84.
270. Jiménez B, Ugwu F, Zhao R, et al. Structure of minimal tetratricopeptide repeat domain protein tah1 reveals mechanism of its interaction with pih1 and hsp90. J Biol Chem 2012; 287: 5698-709.
271. Suzuki Y, Minami M, Suzuki M, et al. The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G. J Biol Chem 2009; 284: 35597-604.